Media Coverage

Ceva showcases new egg injection technique


Sep 12, 2017 - Animal Pharm

By Malcolm Flanagan
Animal Pharm
September 12, 2017


Libourne-headquartered Ceva showcased its latest in ovo vaccination technique at the recent World Veterinary Poultry Association (WVPA) Congress in the Scottish capital Edinburgh.

Ceva said Egginject adapts its injection technique to the shape of every single poultry egg.  This is compared to older systems that simply inject to a uniform depth, which can result in poor or no vaccine uptake.

The company told attendees at its symposium within the WVPA event "it is vital to focus on certain critical factors to achieve completely efficient in ovo vaccination". These include the chick's embryo age and development, new solutions for improved chick quality and essential steps to optimize in ovo vaccination.

Dr Christophe Cazaban, Ceval global veterinary services manager, explained: " We realised that our poultry vaccines were very innovative but unless they are administered properly this means nothing. Continuous improvement as in all industries is made up of small steps/gains our symposium focused on this. If you take for example in-ovo injection, we have now demonstrated scientifically that narrowing down the vaccination window to embryo development between 18.5 and 19 days is optimal disease prevention and growth."

Ceva said to achieve optimum efficiency in poultry prevention strategies, producers are advised to combine Egginject and hatchery automation equipment with the firm's hatchery diagnostic product Laser Life.

The company said Laser Life identifies all live eggs in a singular manner. This is vital in the in ovo vaccination process, as one dead or contaminated egg can spread contamination through injecting equipment causing severe disruption and waste. Any contaminated or diseased eggs are removed by Laser Life thus saving producers time and money.

Dr Sylvain Comte, Ceva's head of poultry, said: "Innovation is the key to this new poultry vaccinology approach. After launching some of the most innovative vaccines that the poultry industry has seen in the last decade, we realized vaccination alone is no longer enough.

"Ensuring that vaccines are applied correctly as part of a total preventative health program is key to the future. We are delighted that internationally respected bodies such as France's Bureau Veritas have independently verified the quality of our service programs. This is just the beginning; we now have to focus on how we can further use the huge amount of data we are collecting to help our customers continuously meet evolving consumer demands. At the same time automation through machines such as Laser Life will help to improve health and management practice by removing non-viable eggs reduces contamination and hence the need to use antibiotics."

Attendees to the WVPA event were also told Ceva has invested heavily in new technology vaccines products such as Transmune (infectious bursal disease) and Vectormune (Newcastle and Marek's disease) in the last decade. In addition, its vaccination quality program CHICK has now been officially approved in South Africa, Spain, Turkey, the Philippines, Mexico, Russia and Poland.
Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum